Israeli Stocks: Dexia, Isras, I.T.G.I., Kamada, Lifewave, Sialo

Israel’s TA-25 Index advanced the most in two weeks, gaining 1 percent to 1,330.54 at the 4:30 p.m. close in Tel Aviv. Investors traded about 972.2 million shekels ($283 million) in shares and convertible securities.

The following stocks rose or fell today. Symbols are in parentheses.

Dexia Israel Bank Ltd. (DXIL IT) jumped 5 percent to 682.50 shekels, the highest level since at least 1995 when Bloomberg began tracking the shares. Dexia SA said it received and is considering several offers for its holdings in the lender.

Isras Investment Company Ltd. (ISRS IT) rose to the highest since January 2008, increasing 7 percent to 139.10 shekels. The building company’s board approved the acquisition of OCIF Investments and Development Ltd. (OCIF IT). OCIF fell 1.5 percent to 17.46 shekels.

I.T.G.I. Medical Ltd. (ITGI IT) climbed to the highest since Feb. 27, gaining 5.9 percent to 0.448 shekel. The maker of vascular products said its pericardium covered stent won international recognition in a cardiovascular magazine.

Kamada Ltd. (KMDA) advanced the most in more than two months, adding 4.5 percent to 31.61 shekels. The biopharmaceutical company received a U.S. patent for use of alpha 1 antitrypsin to treat exacerbation episodes of pulmonary diseases.

Lifewave Ltd. (LIFE) dropped to the lowest since January 2009, losing 3.9 percent to 1.904 shekels. The maker of medical equipment raised 2.2 million shekels from a share sale.

Sialo Technology Israel Ltd. (SALO) increased the most since Jan. 9, climbing 5.4 percent to 1.383 shekels. The developer of surgical equipment signed an agreement with A.D.C. Co. Israel Ltd. to exclusively distribute the company’s dental systems in Russia, Ukraine and Kazakhstan.

To contact the reporter on this story: Ronit Goodman in Tel Aviv at

To contact the editor responsible for this story: Claudia Maedler at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.